Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Since late 2019, the new SARS-CoV-2 virus belonging to the <i>Coronaviridae</i> family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed to fight this not rarely...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/2/214 |
| _version_ | 1797297690963345408 |
|---|---|
| author | Massimo Franchini Daniele Focosi |
| author_facet | Massimo Franchini Daniele Focosi |
| author_sort | Massimo Franchini |
| collection | DOAJ |
| description | Since late 2019, the new SARS-CoV-2 virus belonging to the <i>Coronaviridae</i> family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed to fight this not rarely life-threatening respiratory illness. Among them, however, the only specific antibody-based therapy available against SARS-CoV-2 infection during the first year of the pandemic was represented by COVID-19 convalescent plasma (CCP). CCP, collected from recovered individuals, contains high levels of polyclonal antibodies of different subclasses able to neutralize SARS-CoV-2 infection. Tens of randomized controlled trials have been conducted during the last three years of the pandemic to evaluate the safety and the clinical efficacy of CCP in both hospitalized and ambulatory COVID-19 patients, whose main results will be summarized in this narrative review. In addition, we will present the current knowledge on the development of anti-SARS-CoV-2 hyperimmune polyclonal immunoglobulins. |
| first_indexed | 2024-03-07T22:23:59Z |
| format | Article |
| id | doaj.art-a557aee46abb45b498954bf80e0dbf97 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-07T22:23:59Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-a557aee46abb45b498954bf80e0dbf972024-02-23T15:24:39ZengMDPI AGLife2075-17292024-02-0114221410.3390/life14020214Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative ReviewMassimo Franchini0Daniele Focosi1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, 46100 Mantua, ItalyNorth-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, ItalySince late 2019, the new SARS-CoV-2 virus belonging to the <i>Coronaviridae</i> family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed to fight this not rarely life-threatening respiratory illness. Among them, however, the only specific antibody-based therapy available against SARS-CoV-2 infection during the first year of the pandemic was represented by COVID-19 convalescent plasma (CCP). CCP, collected from recovered individuals, contains high levels of polyclonal antibodies of different subclasses able to neutralize SARS-CoV-2 infection. Tens of randomized controlled trials have been conducted during the last three years of the pandemic to evaluate the safety and the clinical efficacy of CCP in both hospitalized and ambulatory COVID-19 patients, whose main results will be summarized in this narrative review. In addition, we will present the current knowledge on the development of anti-SARS-CoV-2 hyperimmune polyclonal immunoglobulins.https://www.mdpi.com/2075-1729/14/2/214COVID-19SARS-CoV-2convalescent plasmahyperimmune immunoglobulins |
| spellingShingle | Massimo Franchini Daniele Focosi Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review Life COVID-19 SARS-CoV-2 convalescent plasma hyperimmune immunoglobulins |
| title | Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review |
| title_full | Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review |
| title_fullStr | Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review |
| title_full_unstemmed | Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review |
| title_short | Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review |
| title_sort | hyperimmune plasma and immunoglobulins against covid 19 a narrative review |
| topic | COVID-19 SARS-CoV-2 convalescent plasma hyperimmune immunoglobulins |
| url | https://www.mdpi.com/2075-1729/14/2/214 |
| work_keys_str_mv | AT massimofranchini hyperimmuneplasmaandimmunoglobulinsagainstcovid19anarrativereview AT danielefocosi hyperimmuneplasmaandimmunoglobulinsagainstcovid19anarrativereview |